Also, differences in exon coverage of our gene panels could have affected the variability in mutation profiles of tumor samples, although the differences we found in TP53 mutations cannot be fully proven because samples were not tested for all possible genetic aberrations and no statistical validation was performed. Here, TP53 is linked to neoplasm.